In conclusion, CTLA4-Ig enables the modulation of peripheral blood-derived CD4pos cell subtypes in RA patients in terms of Th17 CD4pos cells decrease and a trend toward the normalization of Tregs in parallel with an effect on IL-6 burden. This evidence concerns the gene CTLA4 and rheumatoid arthritis.